Monday, January 16, 2006

Medicare Contractor Establishes Reimbursement Coverage Policy for Genomic Health's Oncotype DX(TM) Breast Cancer Test

PRNewswire, January 16, 2005
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Heritage Insurance Company (NHIC), the contractor that administers Medicare programs in California, has established a positive coverage policy for the company's Oncotype DX(TM) breast cancer test, which quantifies the likelihood of breast cancer recurrence and predicts the likelihood of response to chemotherapy for a large portion of early-stage breast cancer patients. Medicare bills for Oncotype DX are currently billed through NHIC because the test is conducted by Genomic Health in its Redwood City, California clinical reference laboratory. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */